ebook: Waiving intellectual property rights for COVID-19-related interventions and technologies: a comprehensive guide

This ebook explores the intellectual property rights waiver for COVID-19 treatments, vaccines, diagnostics and technologies, its potential ramifications for the drug development industry and potential solutions for overcoming COVID-19 vaccination inequalities.

The call for the World Trade Organization (WTO) to waive certain Trade-Related Intellectual Property Rights (TRIPS) for COVID-19 drugs, vaccines, diagnostics and other technologies for the duration of the pandemic stunned the pharmaceutical, biopharmaceutical and biotechnology industries in October 2020. However, perhaps the most shocking development was when the Biden Administration lent support to the action in May 2021, surprising because the US is well known for being protective of intellectual property (IP).